# Clinical Trial Assessing the HERV-W Env Antagonist GNbAC1 for Efficacy in MS

> **NCT02782858** · PHASE2 · COMPLETED · sponsor: **GeNeuro SA** · enrollment: 270 (actual)

## Conditions studied

- Multiple Sclerosis, Relapsing-Remitting

## Interventions

- **DRUG:** GNbAC1
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT02782858
- **Lead sponsor:** GeNeuro SA
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-04
- **Primary completion:** 2017-08
- **Final completion:** 2017-12
- **Target enrollment:** 270 (ACTUAL)
- **Last updated:** 2020-10-20

## Collaborators

- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02782858

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02782858, "Clinical Trial Assessing the HERV-W Env Antagonist GNbAC1 for Efficacy in MS". Retrieved via AI Analytics 2026-07-04 from https://api.ai-analytics.org/clinical/NCT02782858. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*